Navigation Links
Unilens Vision Reports Increased Royalty Income

21st Consecutive Profitable Quarter Earns $.08 Per Diluted Share

LARGO, Fla., May 28 /PRNewswire-FirstCall/ -- Unilens Vision Inc. (OTC Bulletin Board: UVICF) (TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the third quarter and first nine months of FY2008.

Net sales, excluding royalty income, for the quarter ended March 31, 2008 increased to $1,668,397 compared with $1,634,429 in the prior-year quarter ending March 31, 2007 an increase of 2.1%. The increase was primarily the result of continued growth of the Company's C-Vue multifocal contact lenses, which increased approximately 11% in the current quarter, which was partially offset by sales of our replacement products lines that declined as expected.

Royalty income for the quarter increased 15.3% to $628,993 compared with $545,293 in the prior-year quarter. Sales of licensed products by our licensee Bausch & Lomb continue to increase, resulting in continued double digit royalty income growth.

For the quarter, the Company reported net income of $368,730, or $0.08 per diluted share, compared with net income of $372,355 or $0.08 per diluted share in the prior-year quarter.

For the nine months ended March 31, 2008, net sales excluding royalty income, increased 3.8% to $4,854,119 as compared to $4,677,358 for the prior- year period. Net sales of the Company's C-Vue multifocal contact lenses increased approximately 12% during the first nine months of fiscal year 2008, while sales of replacement products lines declined, as expected.

Net Income for the nine months increased 24.2% to $1,121,941, or $0.25 per diluted share, compared with $903,697, or $0.20 per diluted share in the prior-year period.

Royalty income for the nine months ended March 31, 2008 increased 21.1% to a record $1,888,641, compared with $1,559,496 in the prior-year period, demonstrating continued increased demand for sales of licensed products by our licensee Bausch & Lomb.

"We are pleased to report our 21st consecutive quarter of profitability driven by increased royalty income from Bausch and Lomb's multifocal sales utilizing our patented licensed technology," stated Michael J. Pecora, Chief Executive Officer of Unilens Vision Inc. "Sales of our C-Vue brand disposable multifocal and single vision lenses also continue to steadily increase, achieving double digit growth."

"Earlier this month, we added to our C-Vue brand with the launch of the C- Vue 1DAY daily disposable single vision lens. This new offering expands the Company's portfolio of soft lens products, serving the rapidly growing one- time use daily disposable single vision market," concluded Mr. Pecora. The Company will market the lens under the C-Vue brand exclusively to licensed eye care professionals.

About Unilens Vision Inc. - "The Eye Care Professionals Specialty Contact Lens Company"

Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida, develops, licenses, manufactures, distributes and markets specialty contact lenses under the C- Vue, Unilens, Sof-Form, Aquaflex, SoftCon, Lombart, and LifeStyle brands. Additional information on the Company may be accessed on the Internet at . The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVICF" as well as the Canadian TSX Venture Exchange under the symbol "UVI."

(Note: All financial information in this release is stated in U.S. Dollars.)

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward- looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Leonard F. Barker, CFO, Unilens Vision Inc. at (727) 544-2531




(All figures in U.S. Dollars)


Three Three

Months Months Nine Months Nine Months

Ended Ended Ended Ended

March 31, March 31, March 31, March 31,

2008 2007 2008 2007

Sales $ 1,668,397 $ 1,634,429 $ 4,854,119 $4,677,358

Cost of sales 964,952 855,443 2,754,802 2,569,902

703,445 778,986 2,099,317 2,107,456

Expenses 706,041 698,067 2,176,183 2,186,419

(Loss) income from

operations (2,596) 80,919 (76,866) (78,963)

Other items:

Royalty income 628,993 545,293 1,888,641 1,559,496

Other (expense) income 1,845 (703) (47,071) (390)


income (loss) (1,044) 212 1,968 (1,717)

Interest income 3,995 9,476 23,279 30,845

633,789 554,278 1,866,817 1,588,234

Income before tax 631,193 635,197 1,789,951 1,509,271

Income tax expense 262,463 262,842 668,010 605,574

Net income for the

period $ 368,730 $ 372,355 $ 1,121,941 $ 903,697

Net income per common


Basic $ 0.08 $ 0.08 $ 0.25 $ 0.20

Diluted $ 0.08 $ 0.08 $ 0.25 $ 0.20


Provided (used) by:


activities $ 893,412 $ 739,395 $ 1,848,658 $1,517,749


activities (33,699) (51,187) (63,458) (141,141)

Financing activities (409,564) (326,491) (2,563,136) (1,774,879)

(Decrease) increase

in cash $ 450,149 $ 361,717 $ (777,936) $ (398,271)


June 30, March 31, March 31,

2007 2008 2007

Cash $ 1,961,712 $ 1,185,744 $ 1,795,645

Total assets 7,987,808 6,489,924 7,956,755

Current liabilities 819,005 762,316 855,725

Total liabilities 819,005 762,316 855,725

Stockholders' equity $ 7,168,803 $ 5,727,608 $ 7,101,030

SOURCE Unilens Vision Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Unilens Launches Aspheric C-VUE(R) Daily Disposable Lens
2. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
3. Unilens Vision Reports 70% Increase in Second Quarter Earnings on Higher Sales and Record Royalty Income
4. Unilens Vision Inc. Declares Regular Quarterly Cash Dividend of U.S. $0.09 Per Share
5. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
6. Unilens Names Eschenbach Optik Exclusive Worldwide Distributor of the UniVision(R) Low Vision Lens
7. IMTEC Introduces New Vision Software
8. Delray Beach Soccer Club Signs Division One College Soccer Coaches
9. Lutein and Zeaxanthin Improve Sports Vision for Athletes
10. World Vision Appealing for $2 Million for Deadly China Quake
11. AVMA Declares Preliminary Victory on Farm Bill Provisions
Post Your Comments:
(Date:11/24/2015)... ... ... Bibliomotion is thrilled to announce the launch of UNCONVENTIONAL LEADERSHIP: ... Nancy M. Schlichting, Chief Executive Officer of Henry Ford Health System (November 24, ... patients and their families, shaped my desire to improve the system of care. I ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Kevin Day, local family chiropractor in ... less this holiday season. During the Indiana winter months, Vitamin D deficiency can ... team at AlignLife want to help provide the tools needed to combat it this ...
(Date:11/24/2015)... ... 2015 , ... All her life, Don Peck’s mother wondered if she was a descendant of ... been. After a 25-year search for information, Don and his aunt discovered that she ... name. Turns out, it was Don’s father who was descended from not one, but ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... engineer of patented products, announces Fragrance by Marcelle, a cosmetic invention which offers ... Perfume & Fragrance Manufacturing Market in the US is worth $3 billion annually," ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... of the Business Action on Health Awards, bestowed annually to the world’s best ... five commended companies at Global Health Council’s Landscape Symposium held in Washington D.C ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... -based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ) ... and dispensing of novel compounded pharmaceuticals.  The company,s ... ophthalmology, urology, sinus and integrative medicine.  Imprimis dispenses ... facilities located in California , ... Jersey and Pennsylvania.  For more information ...
(Date:11/24/2015)... NEW YORK , Nov. 24, 2015  Eyewear brand ... sunglasses in collaboration with U2 lead singer and activist Bono ... campaign to prevent vision impairment and blindness in more than ... --> Revo will donate $10 from the sale ... Visibility" collection, up to a total of $10 million to ...
(Date:11/24/2015)... Nov. 24, 2015 Xencor, Inc. (NASDAQ: ... antibodies for the treatment of autoimmune diseases, asthma and ... Dahiyat , Ph.D., president and chief executive officer, will ... , 2015 Piper Jaffray Healthcare Conference Date: Tuesday, December ... New York, NY     , Oppenheimer ...
Breaking Medicine Technology: